Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Sofosbuvir/ledipasvir produces early cure for 100% of people with HIV and HCV co-infection

Treatment for 12 weeks with a co-formulation of sofosbuvir and ledipasvir led to sustained response for all participants with HIV and HCV co-infection who had genotype 1

Published
11 April 2014
By
Liz Highleyman
Sofosbuvir/ledipasvir is safe and effective for relapsers and hard-to-treat patients

A co-formulation of sofosbuvir and ledipasvir successfully treated a variety of difficult-to-treat patient populations including people with hepatitis C virus (HCV) genotype 3, people with decompensated cirrhosis and

Published
11 April 2014
By
Liz Highleyman
88% of previous relapsers achieve hepatitis C cure with simeprevir-based triple therapy

Almost 90% of European patients who had relapsed after previous treatment with pegylated interferon and ribavirin were cured of hepatitis C after 24 weeks of treatment with

Published
10 April 2014
By
Keith Alcorn
AbbVie interferon-free regimen cures 96% of treatment-experienced genotype 1 hepatitis C infections

A 12-week course of three direct-acting antivirals developed by AbbVie, plus ribavirin, cured 96.3% of treatment-experienced patients with hepatitis C genotype 1 infection, Professor Stefan Zeuzem of

Published
10 April 2014
By
Keith Alcorn
Egypt: New Treatments May Defuse Viral Hepatitis Time Bomb

Egypt is said officially to have the highest prevalence of hepatitis C in the world, with 10 to 14 percent of its 85 million people infected, and about two million in dire need of treatment. The Egyptian government recently struck a deal with U.S. pharmaceutical firm Gilead Sciences to purchase its new hepatitis C pill Sovaldi at a fraction of its American price.

Published
10 April 2014
From
Inter Press Service
Gilead aims to license hepatitis C drug to 3-4 Indian firms

Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations.

Published
09 April 2014
From
Reuters
Gilead says has discounted hepatitis C drug for some health plans

Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

Published
31 March 2014
From
Reuters
Interferon-free BMS combo cures 90% of genotype 1 hepatitis C

An all-oral regimen of daclatasvir, asunaprevir and BMS-791325 – without interferon or ribavirin – led to sustained response in approximately 90% of people with hepatitis C virus

Published
26 March 2014
By
Liz Highleyman
Gilead offers Egypt new hepatitis C drug at 99 percent discount

Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price. While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States.

Published
24 March 2014
From
Reuters
US Lawmakers Attack Cost of New Hepatitis Drug

A new drug to treat hepatitis C that costs $1,000 a pill has caused rising concern among insurers and state Medicaid programs. It has now also spurred interest from Democratic congressmen whose queries about the drug prompted a sell-off in biotechnology stocks on Friday.

Published
24 March 2014
From
New York Times

Filter by country